Home Newsfeeds B. Riley Securities Downgrades Identiv to Neutral, Lowers Price Target to $12

B. Riley Securities Downgrades Identiv to Neutral, Lowers Price Target to $12

B. Riley Securities analyst Craig Ellis downgrades Identiv (NASDAQ:INVE) from Buy to Neutral and lowers the price target from $19 to $12.

byBenzinga Newsdesk

November 3, 2022

1 minute read

B. Riley Securities analyst Craig Ellis downgrades Identiv (NASDAQ:INVE) from Buy to Neutral and lowers the price target from $19 to $12.

Analyst Ratings

In-Depth Examination Of 5 Analyst Recommendations For Universal Technical

By Benzinga Insights

December 20, 9:00 AM

Throughout the last three months, 5 analysts have evaluated Universal Technical (NYSE:UTI), offering a diverse set of opinions…

UTI

VeeFriends, Reebok Collaborate On Sneakers Featuring NFT Character: How You Can Get A Pair

By Chris Katje

August 3, 10:09 AM

Entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) is further expanding the intellectual property of his NFT collection with a new collaboration with leading shoe company Reebok.

ETH

GENFIT Announces Publication In Nature Medicine Confirming The Performance Of Its Nash Diagnostic Technology

By Benzinga Newsdesk

September 26, 4:24 PM

GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical companydedicated to improving the lives of patients with rare and severe liver diseases, today announcedthe publication of data demonstrating the

GNFT

FOMC Decision Full Statement (Link In Body)

By Benzinga Newsdesk

November 2, 2:00 PM

November 02, 2022 Federal Reserve issues FOMC statement For release at 2:00 p.m. EDT Share Recent indicators point to modest growth in spending and production. Job gains have been robust in recent months, and the

SPY

B. Riley Securities Downgrades Identiv to Neutral, Lowers Price Target to $12

Related Posts

In-Depth Examination Of 5 Analyst Recommendations For Universal Technical

VeeFriends, Reebok Collaborate On Sneakers Featuring NFT Character: How You Can Get A Pair

GENFIT Announces Publication In Nature Medicine Confirming The Performance Of Its Nash Diagnostic Technology

FOMC Decision Full Statement (Link In Body)